Blog

Bar Levy: Reflections from ASCO 2025 – What should Patient Advocates Take from these Findings?

Bar Levy/LinkedIn

Jun 9, 2025, 04:47

Bar Levy: Reflections from ASCO 2025 – What should Patient Advocates Take from these Findings?

Bar Levy, Founder and CEO of HaBait Shel Bar, posted on LinkedIn:

“Reflections from ASCO 2025: What should Patient Advocates Take from these Findings?

As ASCO 2025 concluded, I find myself reflecting not only on what was said on stage—but what we, as patient advocates, must now do off stage. ASCO 2025 offered us important, sometimes sobering, insights:

Relacorilant + nab-paclitaxel showed OS and PFS benefit in platinum-resistant ovarian cancer, which signal us that there is more to come for those patients who needs new treatment options so much.

Upfront surgery still holds value for certain patients, but not all.

Immunotherapy combinations continue to offer some progress in clear cell ovarian cancer, not only on cervical cancer or endometrial cancer.

Gene therapies and CDK2 inhibitors signal a future that is exciting, yet still far from accessible.

In vulvar cancer, we saw new combination that improve survival and bring hope to this rare disease patients!!!! But it reminds us that disparities remain vast.

The question that raises now is what is our role now, as patient advocates?

These results are not just about molecules. They are about market access, infrastructure, and equity.
Translating survival curves into real-world survivorship is complex — with paying attention to quality of life, sexual health, and long-term side affects. We must prepare our communities now for treatments that may arrive later—by educating and empowering the patients, but also by advocating for readiness of the governments to reimburse and administrate those exciting options. It’s all about collaboration – we need to collaborate across countries to ensure that innovations are not only for the few, but for the many.

I have to keep repeating my agenda – This is why patient advocacy is not just a voice in the room—it is a bridge between innovation and implementation. Between policy and person. Between science and soul.

To all fellow advocates, HCPs professionals, and allies: Let’s lead the change together.”